These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38401422)

  • 21. Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer.
    Seligson JM; Patron AM; Berger MJ; Harvey RD; Seligson ND
    Ann Pharmacother; 2021 Jul; 55(7):921-931. PubMed ID: 33070624
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety evaluation of Datopotamab deruxtecan for triple-negative breast cancer: a meta-analysis.
    Gadaleta-Caldarola G; Lanotte L; Infusino S; Gadaleta-Caldarola A; Schipilliti FM; Citrigno C; Petrarota C; Cusmai A; Rizzo A
    Cancer Treat Res Commun; 2023; 37():100775. PubMed ID: 37956525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The evolving management of metastatic triple negative breast cancer.
    Malhotra MK; Emens LA
    Semin Oncol; 2020 Aug; 47(4):229-237. PubMed ID: 32563561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody-Drug Conjugate Revolution in Breast Cancer: The Road Ahead.
    Grinda T; Rassy E; Pistilli B
    Curr Treat Options Oncol; 2023 May; 24(5):442-465. PubMed ID: 36966267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of sacituzumab govitecan in solid tumors.
    Veeraballi S; Khawar Z; Aslam HM; Muzaffar M
    J Oncol Pharm Pract; 2022 Oct; 28(7):1617-1623. PubMed ID: 35404158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
    O'Shaughnessy J; Brufsky A; Rugo HS; Tolaney SM; Punie K; Sardesai S; Hamilton E; Loirat D; Traina T; Leon-Ferre R; Hurvitz SA; Kalinsky K; Bardia A; Henry S; Mayer I; Zhu Y; Phan S; Cortés J
    Breast Cancer Res Treat; 2022 Sep; 195(2):127-139. PubMed ID: 35545724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2- Breast Cancer.
    Kang C
    Target Oncol; 2024 Mar; 19(2):289-296. PubMed ID: 38446351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
    Bardia A; Mayer IA; Diamond JR; Moroose RL; Isakoff SJ; Starodub AN; Shah NC; O'Shaughnessy J; Kalinsky K; Guarino M; Abramson V; Juric D; Tolaney SM; Berlin J; Messersmith WA; Ocean AJ; Wegener WA; Maliakal P; Sharkey RM; Govindan SV; Goldenberg DM; Vahdat LT
    J Clin Oncol; 2017 Jul; 35(19):2141-2148. PubMed ID: 28291390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Sacituzumab-govitecan in hormone-receptor positive/HER2-negative advanced breast cancer].
    Besnainou H; Cabel L
    Bull Cancer; 2024 Apr; 111(4):333-334. PubMed ID: 38458926
    [No Abstract]   [Full Text] [Related]  

  • 30. Sacituzumab govitecan activity in advanced breast cancer.
    Burki TK
    Lancet Oncol; 2017 May; 18(5):e246. PubMed ID: 28343977
    [No Abstract]   [Full Text] [Related]  

  • 31. Sacituzumab govitecan (Trodelvy) for metastatic triple-negative breast cancer.
    Med Lett Drugs Ther; 2021 Feb; 63(1617):e25-e27. PubMed ID: 33757114
    [No Abstract]   [Full Text] [Related]  

  • 32. Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer.
    Schettini F; Venturini S; Giuliano M; Lambertini M; Pinato DJ; Onesti CE; De Placido P; Harbeck N; Lüftner D; Denys H; Van Dam P; Arpino G; Zaman K; Mustacchi G; Gligorov J; Awada A; Campone M; Wildiers H; Gennari A; Tjan-Heijnen V; Bartsch R; Cortes J; Paris I; Martín M; De Placido S; Del Mastro L; Jerusalem G; Curigliano G; Prat A; Generali D
    Cancer Treat Rev; 2022 Dec; 111():102468. PubMed ID: 36202026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential.
    Rizzo A; Cusmai A; Acquafredda S; Rinaldi L; Palmiotti G
    Expert Opin Investig Drugs; 2022 Jun; 31(6):495-498. PubMed ID: 35171746
    [No Abstract]   [Full Text] [Related]  

  • 34. ESMO20 YO for YO: highlights on new drugs in advanced breast cancer focusing on sacituzumab govitecan and alpelisib.
    Lambertini M; Punie K
    ESMO Open; 2021 Feb; 6(1):100018. PubMed ID: 33399081
    [No Abstract]   [Full Text] [Related]  

  • 35. The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer.
    Michaleas S; Moreno Oliver A; Mueller-Berghaus J; Sarac SB; van der Elst ME; Müller-Egert S; Zander H; Enzmann H; Pignatti F
    ESMO Open; 2022 Jun; 7(3):100497. PubMed ID: 35642987
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.
    Rugo HS; Bardia A; Marmé F; Cortés J; Schmid P; Loirat D; Trédan O; Ciruelos E; Dalenc F; Gómez Pardo P; Jhaveri KL; Delaney R; Valdez T; Wang H; Motwani M; Yoon OK; Verret W; Tolaney SM
    Lancet; 2023 Oct; 402(10411):1423-1433. PubMed ID: 37633306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiotoxicity of Agents Used in Patients With Breast Cancer.
    Zagami P; Trapani D; Nicolò E; Corti C; Valenza C; Criscitiello C; Curigliano G; Carey LA
    JCO Oncol Pract; 2024 Jan; 20(1):38-46. PubMed ID: 37983586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors.
    Fenn KM; Kalinsky K
    Drugs Today (Barc); 2019 Sep; 55(9):575-585. PubMed ID: 31584574
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New data for sacituzumab govitecan-hziy in the treatment of metastatic triple-negative breast cancer.
    Bardia A
    Clin Adv Hematol Oncol; 2021 Nov; 19(11):723-725. PubMed ID: 34807017
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical development of antibody-drug conjugates in triple negative breast cancer: can we jump higher?
    Zardavas D
    Expert Opin Investig Drugs; 2022 Jun; 31(6):633-644. PubMed ID: 35451891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.